Elize Pietersen

Elize Pietersen

Auto-generated profile, based on publicly available information

Elize Pietersen

Department of Medicine and UCT Lung Institute & South African MRC/UCT Centre for the Study of Antimicrobial Resistance, Division of Pulmonology, Centre for Lung Infection and Immunity, University of Cape Town, Cape Town, South Africa

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2020 in Nature Medicine
Verified
Journal Article
Open access
PDF file
GTGrant Theron
Grant Theron
JLJason Limberis
Jason Limberis
RVRouxjeane Venter
Rouxjeane Venter
LSLiezel Smith
Liezel Smith
EPElize Pietersen
Elize Pietersen
KDKeertan Dheda
Keertan Dheda
A burgeoning epidemic of drug-resistant tuberculosis (TB) threatens to derail global control efforts. Although the mechanisms remain poorly clarified, drug-resistant strains are widely believed to be less infectious than drug-susceptible strains. Consequently, we hypothesized that lower proportions of patients with drug-resistant TB would have culturable Mycobacterium tuberculosis from respirable, cough-generated aerosols compared to patients with drug-susceptible TB, and that multiple factors, including mycobacterial genomic variation, would predict culturable cough aerosol production. We enumerated the colony forming units in aerosols (≤10 µm) from 452 patients with TB (227 with drug resistance), compared clinical characteristics, and performed mycobacterial whole-genome sequencing, dormancy phenotyping and drug-susceptibility analyses on M. tuberculosis from sputum. After considering treatment duration, we found that almost half of the patients with drug-resistant TB were cough aerosol culture-positive. Surprisingly, neither mycobacterial genomic variants, lineage, nor dormancy status predicted cough aerosol culture positivity. However, mycobacterial sputum bacillary load and clinical characteristics, including a lower symptom score and stronger cough, were strongly predictive, thereby supporting targeted transmission-limiting interventions. Effective treatment largely abrogated cough aerosol culture positivity; however, this was not always rapid. These data question current paradigms, inform public health strategies and suggest the need to redirect TB transmission-associated research efforts toward host–pathogen interactions.

13 February 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EPElize Pietersen
Elize Pietersen
KAKim Anderson
Kim Anderson
HCHelen Cox
Helen Cox
KDKeertan Dheda
Keertan Dheda
ABAihua Bian
Aihua Bian
YHYuri F van der Heijden
Yuri F van der Heijden
Background: Updated World Health Organization (WHO) treatment guidelines prioritize all-oral drug-resistant tuberculosis (DR-TB) regimens. Several poorly tolerated drugs, such as amikacin and para-aminosalicylic acid (PAS), remain treatment options for DR-TB in WHO-recommended longer regimens as Group C drugs. Incomplete treatment with anti-TB drugs increases the risk of treatment failure, relapse, and death. We determined whether missed doses of individual anti-TB drugs, and reasons for their discontinuation, varied in closely monitored hospital settings prior to the 2020 WHO DR-TB treatment guideline updates. Methods: We collected retrospective data on adult patients with microbiologically confirmed DR-TB between 2008 and 2015 who were selected for a study of acquired drug resistance in the Western Cape Province of South Africa. Medical records through mid-2017 were reviewed. Patients received directly observed treatment during hospitalization at specialized DR-TB hospitals. Incomplete treatment with individual anti-TB drugs, defined as the failure to take medication as prescribed, regardless of reason, was determined by comparing percent missed doses, stratified by HIV status and DR-TB regimen. We applied a generalized mixed effects model. Results: Among 242 patients, 131 (54%) were male, 97 (40%) were living with HIV, 175 (72%) received second-line treatment prior to first hospitalization, and 191 (79%) died during the study period. At initial hospitalization, 134 (55%) patients had Mycobacterium tuberculosis with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]) without resistance to ofloxacin or amikacin, and 102 (42%) had resistance to ofloxacin and/or amikacin. Most patients (129 [53%]) had multiple hospitalizations and DST changes occurred in 146 (60%) by the end of their last hospital discharge. Incomplete treatment was significantly higher for amikacin (18%), capreomycin (18%), PAS (17%) and kanamycin (16%) than other DR-TB drugs (P<0.001), including ethionamide (8%), moxifloxacin (7%), terizidone (7%), ethambutol (7%), and pyrazinamide (6%). Among the most frequently prescribed drugs, second-line injectables had the highest rates of discontinuation for adverse events (range 0.56–1.02 events per year follow-up), while amikacin, PAS and ethionamide had the highest rates of discontinuation for patient refusal (range 0.51–0.68 events per year follow-up). Missed doses did not differ according to HIV status or anti-TB drug combinations. Conclusion: We found that incomplete treatment for second-line injectables and PAS during hospitalization was higher than for other anti-TB drugs. To maximize treatment success, interventions to improve person-centered care and mitigate adverse events may be necessary in cases when PAS or amikacin (2020 WHO recommended Group C drugs) are needed.

6 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
KDKeertan Dheda
Keertan Dheda
SOSuzette Oelofse
Suzette Oelofse
AEAliasgar Esmail
Aliasgar Esmail
EPElize Pietersen
Elize Pietersen
SMStuart Meier
Stuart Meier
NNNorbert Ndjeka
Norbert Ndjeka
Background: Rifampicin-resistant tuberculosis (RR-TB) remains a threat to global TB control. The shorter (~6-month) all-oral bedaquiline-pretomanid-linezolid (BPaL) ± fluoroquinolone regimens have been endorsed by the WHO based on published trial data. However, programmatic data regarding its efficacy and safety remain limited.Methods: In this observational cohort study, we evaluated programmatic data from 8,736 RR-TB patients registered on the Electronic-Drug-Resistant-TB-Web-application (EDRWeb) between September 2022 and March 2025 across 5 high-burden South African provinces. We compared the ~6-month BPaL or BPaL with levofloxacin (BPaL/L) regimens with the superseded all-oral bedaquiline-linezolid-containing regimens (9–20-months). WHO-defined treatment-related outcomes were compared using regression models. Clinical characteristics and adverse events were compared descriptively, and time-to-event analyses were performed.Findings: 7504 (85·9%) eligible patients were included in the analysis. After adjusting for potential confounders (previous RR-TB, HIV, body-mass-index, haemoglobin and sputum smear positivity), BPaL/L were associated with significantly lower odds (95% CI) of unfavourable treatment outcomes [adjusted odds ratio (aOR) 0·46 (0·39 – 0·55); p<0·0001]. The proportion of unfavourable outcomes was lower with BPaL/L than with prior regimens [570/2965 (19·2%) vs 1543/4539 (34·0%); p<0·0001], driven primarily by fewer deaths [211/2965 (7·1%) vs 574/4539 (12·7%); p<0·0001] and less loss to follow-up [289/2965 (9·8%) vs 852/4539 (18·8%); p<0·0001]. Independent predictors of unfavourable outcome with BPaL/L were previous RR-TB, and moderate-to-severe anaemia (p<0·05). Fewer severe (Grade 3–5) adverse events were seen with BPaL/L [229/919 (24·9%) vs 528/1511 (34·9%); OR 0·62 (0·52 – 0·74); p<0·0001].Interpretation: In routine practice, 6-month BPaL/L regimens improved clinical outcomes and reduced severe toxicity compared to prior, longer all-oral regimens. However, one-in-five patients still experienced an unfavourable outcome, and treatment related adverse events remained common. These findings inform clinical management and underscore the need for more effective regimen development for DR-TB.Funding: SA Medical Research Council; European and Developing Countries Clinical Trials Partnership; National Research Foundation.

6 January 2022 in Public Health Nursing
Verified
Journal Article
Open access
PDF file
EPElize Pietersen
Elize Pietersen
KAKim Anderson
Kim Anderson
YHYuri F. Heijden
Yuri F. Heijden
Objective Public health nurses (PHN) are key partners in continuity of care for drug-resistant tuberculosis (DR-TB) patients. We examined complexities in DR-TB care transition between community- and hospital-based care. Design We conducted a case study using medical record data. Four patients were purposively selected to illustrate intersectional complexities in DR-TB care transition involving PHN. Results Case A (HIV negative male) received PHN care at a community-based facility 124 km from Cape Town. Cases B, C, and D (males living with HIV) received PHN community-based care, averaging 25 km from the hospital. Treatment failed in cases A, B, and C; they subsequently died. Case D was cured. All cases were granted leave of absence at least once while hospitalized. None returned when expected mainly due to lack of transport funds. PHN played critical roles regarding patients’ return by conducting home visits, interacting with relatives, and assisting emergency officers to transport patients back to the hospital. PHN supported relatives to endure protracted patient hospitalizations. Conclusion The role of PHN in continuity of DR-TB care in low-middle income countries is unambiguous. PHN are key partners in the DR-TB care cascade, namely facilitating retention in care between hospital and community-based care. Effective DR-TB control relies on effective partnerships among healthcare personnel, patients, and their families.